Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2016

View Archived Issues

MedImmune and Abpro to collaborate in developing bispecific antibody

Positive interim data of phase II study of inclisiran at 90 days

Preclinical data on RG-7386 in solid tumors

CytRx reports updated findings from phase III trial of aldoxorubicin for soft tissue sarcomas

Voyager Therapeutics exercises options for rights to NAV vectors

TPC-107, shows high efficacy in cancer tumor mouse models

A tetravalent vaccine candidate against lymphatic filariasis

First-in-human trial finds synthetic preimplantation factor safe and well tolerated

Global Blood Therapeutics' GBT-440 granted orphan designation in E.U.

Ultragenyx Pharmaceutical reports 78-week data from phase II study of UX-007

FDA clears IND for KN-035

Viracta Therapeutics completes acquisition of HDAC inhibitor from Chroma Therapeutics

Bicycle Therapeutics establishes bicyclic peptide collaboration with AstraZeneca

BiondVax's universal flu vaccine safe, well tolerated in phase II study

FDA accepts for review sNDA for expanded label of Abilify Maintena

FDA grants orphan drug designation to risankizumab

Chugai files for approval of Actemra for additional indication in Japan

Naia submits IND application to initiate phase Ib trial of NB-1001 in short bowel syndrome

Five of ProMIS Neurosciences' MAbs for Alzheimer's block prion-like propagation

Bioavailability results presented for GSP-301 at ACAAI

Committee recommends continuation of phase III study of ThermoDox in liver cancer

MicuRx Pharmaceuticals begins phase I study of MRX-4

Tangrun Pharmaceuticals patents agents for HCV infection

Australian institutes describe IRAP inhibitors

Selvita reports PFKFB inhibitors in patent

Roche patent describes TLR7 agonists for HBV infections

Boehringer Ingelheim prepares and tests IGF-1R inhibitors

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...